GlobeNewswire Inc.·2d ago·NaAltimmune Raises $225M in Oversubscribed Offering to Fund MASH TrialAltimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each. ALTwarrantspublic offering
GlobeNewswire Inc.··Na